Trends in Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus Prevalence, Risk Behaviors, and Preventive Measures among Seattle Injection Drug Users Aged 18–30 Years, 1994–2004
Injection drug users (IDUs) are at risk for infection with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Information on time trends in prevalence of these viruses among IDUs and in behaviors influencing their transmission can help define the status of these epidemics and of public health efforts to control them. We conducted a secondary data analysis combining cross-sectional data from IDUs aged 18–30 years enrolled in four Seattle-area studies from 1994 to 2004. Participants in all four studies were tested for antibody to HIV (anti-HIV), hepatitis B core antigen (anti-HBc), and HCV (anti-HCV), and completed behavioral risk assessments. Logistic regression was used to investigate trends in prevalence over time after controlling for sociodemographic, drug use, and sexual behavior variables. Between 1994 and 2004, anti-HBc prevalence declined from 43 to 15% (p < 0.001), anti-HCV prevalence fell from 68 to 32% (p < 0.001) and anti-HIV prevalence remained constant at 2–3%. Declines in anti-HBc and anti-HCV prevalence were observed within the individual studies, although not all these declines were statistically significant. The declines in anti-HBc and anti-HCV prevalence remained significant after control for confounding. Although we did not observe coincident declines in injection equipment sharing practices, there were increases in self-reported needle-exchange use, condom use, and hepatitis B vaccination. We conclude that there has been a substantial and sustained reduction in prevalence rates for HBV and HCV infection among young Seattle IDUs, while HIV rates have remained low and stable.
KeywordsHIV Hepatitis B Hepatitis C Injection drug users Adolescents Needle sharing Needle exchange Hepatitis B vaccination
- 1.Centers for Disease Control and Prevention. HIV/AIDS surveillance Report, 2005. Vol. 17. 2005. Atlanta, GA. U.S. Department of Health and Human Services. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports.
- 3.Nelson KE, Thomas DL. Viral Hepatitis. In: Nelson KE, Williams CM, Graham NMG, eds. Infectious Disease Epidemiology: Theory and Practice. Gaithersburg, MD: Aspen Publishing; 2001:567–609.Google Scholar
- 4.Centers for Disease Control and Prevention. Disease burden from hepatitis A, B, and C in the United States. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/disease_burden.pdf. Accessed on February 5, 2007.
- 6.Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 61. Atlanta, GA: U.S. Department of Health and Human Services; 2006.Google Scholar
- 7.Centers for Disease Control and Prevention. Unpublished data. 2006.Google Scholar
- 22.Breslow NE, Day NE. Statistical Methods in Cancer Research. Lyon: IARC; 1980.Google Scholar
- 23.SPSS, version 14. Chicago, IL; 2004.Google Scholar
- 33.Centers for Disease Control and Prevention. HBV vaccination among high-risk adolescents and adults—San Diego, Califorinia, 1998–2001. MMWR Morb Mortal Wkly Rep. 2002;51:618–621.Google Scholar
- 37.Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR–13):1–19.Google Scholar
- 38.Centers for Disease Control and Prevention. Update: Recommendations to prevent HBV virus transmission—United States. MMWR Morb Mortal Wkly Rep. 1995;44:574–575.Google Scholar
- 39.Centers for Disease Control and Prevention. Notice to readers update: recommendations to prevent hepatitis B transmission—United States. MMWR Morb Mortal Wkly Rep. 1999;48:33–34.Google Scholar